

Notice of Corporate Officer Change

March 1, 2023, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (hereinafter, Santen) today announced the following executive management change, effective March 1st. Rie Nakajima will join the Executive Management Team (EMT), which has responsibility for company management.

Executive management change effective March 1st, 2023

Name	New Title
Rie Nakajima	Corporate Officer Chief Operating Officer

Biography: Rie Nakajima

Rie Nakajima joined Santen on March 1st, 2023 as Corporate Officer, Chief Operating Officer. In addition to strategic functions such as corporate strategy, portfolio management and new business development, and executive functions such as commercial excellence, she will promote strategic global operations by overseeing each regional business. Over the last 20 years, Rie has had a wide range of experience in the automotive industry, management consulting, and the pharmaceutical industry. Especially in the pharmaceutical industry, she has managed global organizations mainly in the areas of management strategy and commercial excellence in Japan, Asia and Europe. She is expected to improve corporate value by leveraging her global experience and strengthening strategy planning and execution.

Rie began her career in Japan gaining a wide range of experience in sales, overseas business and production control at Toyota Motor Corporation. After joining Boston Consulting Group, she led projects for companies in a variety of industries, including the pharmaceutical sector. In 2011, she joined MSD Japan and was in charge of long-term strategy development, new business development and multi-channel marketing strategy in the corporate strategy department. After accumulating experience in sales and marketing, she was appointed Corporate Officer in charge of corporate strategy in 2016. She concurrently served as Corporate Officer in charge of supply chain in 2018 and became president of MSD Taiwan in 2019. In 2021, in conjunction with MSD's spin-off of Organon, which focuses on gynecology, she moved to Switzerland and served as global strategy and innovation lead and has contributed to its business.

Rie holds an MBA from Harvard Business School and a Bachelor of Arts degree in law from the University of Tokyo.

About Santen

As a specialized company dedicated to eye health, Santen carries out research, development, marketing,

and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries and regions. Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator,” Santen aims to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

For more information, please visit Santen’s website (<https://www.santen.com/en/>).

Contact

Corporate Communications

Santen Pharmaceutical Co., Ltd.

E-mail: communication@santen.com